ProfileGDS5678 / 1417264_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 79% 78% 78% 80% 80% 77% 83% 79% 79% 78% 79% 79% 79% 79% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.4551879
GSM967853U87-EV human glioblastoma xenograft - Control 25.4631578
GSM967854U87-EV human glioblastoma xenograft - Control 35.4525378
GSM967855U87-EV human glioblastoma xenograft - Control 45.8262280
GSM967856U87-EV human glioblastoma xenograft - Control 55.7544280
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.1395477
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.9064883
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.4946679
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.4567879
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.4721678
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.4417279
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.4962279
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.4507179
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.4420679